Vycor Medical is a medical device company that was founded as a limited liability company in New York on June 17 2005 under the name Vycor Medical LLC. The entity converted to a Delaware corporation on August 14 2007 and adopted the name Vycor Medical Inc. Its stock became effective in February 2009. In November 2010 Vycor acquired substantially all of the assets of NovaVision Inc and in January 2012 through its wholly owned NovaVision subsidiary it acquired all shares of…
Vycor Medical is a medical device company that was founded as a limited liability company in New York on June 17 2005 under the name Vycor Medical LLC. The entity converted to a Delaware corporation on August 14 2007 and adopted the name Vycor Medical Inc. Its stock became effective in February 2009. In November 2010 Vycor acquired substantially all of the assets of NovaVision Inc and in January 2012 through its wholly owned NovaVision subsidiary it acquired all shares of Sight Science Limited a former competitor of NovaVision. Today Vycor Medical operates two distinct business units within the medical device industry: one unit designs develops and markets neurosurgical access devices and the other unit provides non invasive vision rehabilitation therapies for patients with neurological injury.
Revenue is generated primarily through the sale of the ViewSite Brain Access System and its associated accessories to hospitals and surgical centers. The company also earns income from the provision of non invasive computer based therapy programs including Vision Restoration Therapy and NeuroEyeCoach to patients and rehabilitation providers. Additional revenue streams arise from technical support training and maintenance services offered for both the neurosurgical devices and the therapy platforms. Vycor Medical pursues growth by increasing market penetration in the United States expanding international presence in underrepresented territories and developing new product applications for a broader range of pathologies. In August 2024 the company engaged Maxim Group LLC to assist with strategic acquisitions and partnerships aimed at accelerating growth.
The company operates through the following segments: Vycor Medical and NovaVision.
- Vycor Medical designs develops and markets the ViewSite Brain Access System a retractable access device intended for use in brain and spine surgeries. The product has received FDA 510(k) clearance and bears CE marking for distribution in Europe as a Class III device under the EU MDR. Vycor Medical holds ISO 13485:2016 certification and is MDSAP compliant demonstrating adherence to international quality management standards. The company also possesses a Health Canada Medical Device License for its VBAS products and has obtained regulatory approvals in several other international markets. These credentials support the commercialization of the access system in North America Europe and other regions.
- NovaVision provides non invasive computer based rehabilitation therapies aimed at individuals who have suffered vision loss due to stroke or other brain injury. Its principal offerings include Vision Restoration Therapy and NeuroEyeCoach which are delivered through software based exercises. The VRT product has obtained FDA 510(k) clearance while NeuroEyeCoach is classified as an exempt Class 1 device. NovaVision holds CE mark registrations for its VRT and NeuroEyeCoach products in Europe as Class I devices. The company seeks to expand the reach of its therapy platform by partnering with entities that have direct access to end users or the technological capability to integrate the therapy into digital health and non medical applications.
Vycor Medical occupies a specialized niche within the broader medical device market focusing on neurosurgical access and vision rehabilitation. The company differentiates itself through its proprietary retractable access system and its portfolio of non invasive therapy software. Regulatory certifications such as ISO 13485:2016 MDSAP and various CE markings provide a foundation for product acceptance in regulated markets. With a small workforce of seven employees Vycor Medical leverages joint resources across its divisions to operate efficiently. The firm continues to pursue growth through market expansion product development and strategic partnerships as outlined in its 2024 engagement with Maxim Group LLC.
The company sells its neurosurgical access devices to hospitals surgical centers and specialized neurosurgery departments that perform brain and spine operations. Its vision rehabilitation therapies are provided to patients undergoing post injury recovery as well as to rehabilitation clinics and healthcare professionals who administer the treatment. Vycor Medical does not disclose specific customer names in its public filings but its market includes institutions and providers in the United States Europe and other regions where its products are registered. The firm relies on a combination of direct sales efforts and distribution partners to reach its end users.